Benefits Seen With Losmapimod ‘First’ for FSHD Trial, Fulcrum Says

Benefits Seen With Losmapimod ‘First’ for FSHD Trial, Fulcrum Says

302457

Benefits Seen With Losmapimod ‘First’ for FSHD Trial, Fulcrum Says

Losmapimod, a potential oral treatment for facioscapulohumeral muscular dystrophy (FSHD), missed its main goal in a recent Phase 2 clinical trial, but its developer, Fulcrum Therapeutics, sees this as a constructive failure. Lessons learned will help to shape losmapimod’s continued development, which is supported by the secondary trial goals — and clinically relevant benefits — seen over placebo after almost a year of treatment. “I think the take-home message is that … losmapimod has the…

You must be logged in to read/download the full post.